Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MDGL 
Madrigal Pharmaceuticals Inc (MDGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MDGL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $423.14
Year Target Price $423.14
| 10 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.55% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.68B USD | Price to earnings Ratio - | 1Y Target Price 423.14 |
Price to earnings Ratio - | 1Y Target Price 423.14 | ||
Volume (30-day avg) 15 | Beta -1.08 | 52 Weeks Range 200.63 - 377.46 | Updated Date 06/30/2025 |
52 Weeks Range 200.63 - 377.46 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -17.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -123.38% | Operating Margin (TTM) -57.79% |
Management Effectiveness
Return on Assets (TTM) -25.56% | Return on Equity (TTM) -50.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5956782422 | Price to Sales(TTM) 21.04 |
Enterprise Value 5956782422 | Price to Sales(TTM) 21.04 | ||
Enterprise Value to Revenue 18.77 | Enterprise Value to EBITDA -8.32 | Shares Outstanding 22203300 | Shares Floating 10955099 |
Shares Outstanding 22203300 | Shares Floating 10955099 | ||
Percent Insiders 7.81 | Percent Institutions 108.17 |
Analyst Ratings
Rating 4 | Target Price 423.14 | Buy 3 | Strong Buy 10 |
Buy 3 | Strong Buy 10 | ||
Hold 1 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Madrigal Pharmaceuticals Inc
Company Overview
History and Background
Madrigal Pharmaceuticals, Inc. was founded in 2006. The company focuses on developing therapeutics for non-alcoholic steatohepatitis (NASH) and related metabolic and cardiovascular diseases.
Core Business Areas
- Therapeutics Development: Focuses on the discovery, development, and commercialization of innovative therapies for diseases with high unmet medical need, particularly in the NASH space.
Leadership and Structure
Bill Sibold is the CEO. The organizational structure consists of research and development, clinical operations, and commercial teams.
Top Products and Market Share
Key Offerings
- Resmetirom (MAVRIC-NASH): Resmetirom, a thyroid hormone receptor-u03b2 (THR-u03b2) selective agonist, is Madrigal's lead product candidate for the treatment of NASH. If approved, Resmetirom could capture a significant share of the NASH market, estimated to be worth billions of dollars annually. Competitors include Intercept Pharmaceuticals (OCAX) and others developing NASH therapies.
Market Dynamics
Industry Overview
The NASH market is a large and rapidly growing market driven by the increasing prevalence of obesity and related metabolic diseases. There is a high unmet need for effective therapies.
Positioning
Madrigal is positioning itself as a leader in the NASH space with Resmetirom, which has shown promising results in clinical trials. The company's competitive advantage lies in its selective THR-u03b2 agonist mechanism of action.
Total Addressable Market (TAM)
The estimated total addressable market (TAM) for NASH is estimated at $30-40 billion. With Resmetirom, Madrigal is well positioned to capture a significant portion of this market, especially if it becomes the first-to-market therapy.
Upturn SWOT Analysis
Strengths
- Promising clinical trial results for Resmetirom
- Strong intellectual property position
- Experienced management team
- Focus on a high-unmet-need market
Weaknesses
- Reliance on a single product candidate
- Regulatory approval risks
- Commercialization challenges
- High cash burn rate
Opportunities
- Potential for regulatory approval of Resmetirom
- Expansion into other indications
- Partnerships and collaborations
- Market growth due to increasing NASH prevalence
Threats
- Competition from other NASH therapies
- Regulatory setbacks
- Pricing and reimbursement pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- OCAX
- GILD
- NVS
Competitive Landscape
Madrigal faces competition from other pharmaceutical companies developing NASH therapies. Its advantage lies in Resmetirom's potential efficacy and safety profile.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by clinical trial progress and investor interest in the NASH market.
Future Projections: Future growth is heavily dependent on the regulatory approval and commercial success of Resmetirom. Analyst estimates vary widely.
Recent Initiatives: Focus on completing clinical trials for Resmetirom and preparing for potential commercial launch.
Summary
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on NASH. The company's success hinges on the approval and commercialization of Resmetirom. Positive clinical data provides strong momentum, but regulatory hurdles and competition remain. Maintaining a strong cash position is crucial for ongoing development and commercial launch.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Madrigal Pharmaceuticals Inc
Exchange NASDAQ | Headquaters West Conshohocken, PA, United States | ||
IPO Launch date 2007-02-06 | CEO, President & Director Mr. William J. Sibold | ||
Sector Healthcare | Industry Biotechnology | Full time employees 528 | Website https://www.madrigalpharma.com |
Full time employees 528 | Website https://www.madrigalpharma.com | ||
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.